

AD8 Dementia Screening Interview

Patient ID#: _____

CS ID#: _____

Date: _____

Remember, "Yes, a change" indicates that there has been a change in the last several years caused by cognitive (thinking and memory) problems.	YES, A change	NO, No change	N/A, Don't know
1. Problems with judgment (e.g., problems making decisions, bad financial decisions, problems with thinking)			
2. Less interest in hobbies/activities			
3. Repeats the same things over and over (questions, stories, or statements)			
4. Trouble learning how to use a tool, appliance, or gadget (e.g., VCR, computer, microwave, remote control)			
5. Forgets correct month or year			
6. Trouble handling complicated financial affairs (e.g., balancing checkbook, income taxes, paying bills)			
7. Trouble remembering appointments			
8. Daily problems with thinking and/or memory			
TOTAL AD8 SCORE			

The AD8 Administration and Scoring Guidelines

A spontaneous self-correction is allowed for all responses without counting as an error.

The questions are given to the respondent on a clipboard for self-administration or can be read aloud to the respondent either in person or over the phone. It is preferable to administer the AD8 to an informant, if available. If an informant is not available, the AD8 may be administered to the patient.

When administered to an informant, specifically ask the respondent to rate change in the patient.

When administered to the patient, specifically ask the patient to rate changes in his/her ability for each of the items, **without** attributing causality.

If read aloud to the respondent, it is important for the clinician to carefully read the phrase as worded and give emphasis to note changes due to cognitive problems (not physical problems). There should be a one second delay between individual items.

No timeframe for change is required.

The final score is a sum of the number items marked “Yes, A change”.

Interpretation of the AD8 (Adapted from Galvin JE et al, The AD8, a brief informant interview to detect dementia, *Neurology* 2005;65:559-564)

A screening test in itself is insufficient to diagnose a dementing disorder. The AD8 is, however, quite sensitive to detecting early cognitive changes associated many common dementing illness including Alzheimer disease, vascular dementia, Lewy body dementia and frontotemporal dementia.

Scores in the impaired range (see below) indicate a need for further assessment. Scores in the “normal” range suggest that a dementing disorder is unlikely, but a very early disease process cannot be ruled out. More advanced assessment may be warranted in cases where other objective evidence of impairment exists.


Based on clinical research findings from 995 individuals included in the development and validation samples, the following cut points are provided:

- 0 – 1: Normal cognition
- 2 or greater: Cognitive impairment is likely to be present

Administered to either the informant (preferable) or the patient, the AD8 has the following properties:

- Sensitivity > 84%
- Specificity > 80%
- Positive Predictive Value > 85%
- Negative Predictive Value > 70%
- Area under the Curve: 0.908; 95%CI: 0.888-0.925

Receiver Operator Characteristics (ROC) curve for AD8



Copyright 2005. The *Eight-item Interview to Differentiate Aging and Dementia* is a copyrighted instrument of Washington University, St. Louis, Missouri. All Rights Reserved.

Permission Statement

Washington University grants permission to use and reproduce The AD8: The Washington University Dementia Screening Test, also referred to as the "Eight-item Interview to Differentiate Aging and Dementia" (the "AD8"), without modification or editing of any kind solely for (1) clinical care purposes, defined as a physician's use of the AD8 for non-research patient care services, and (2) non-commercial research, defined as investigator-initiated clinical research that is not funded or supported, in whole or in part, by any for-profit entity (collectively, the "Purpose"). The Purpose specifically excludes any use, reproduction, publication, and/or distribution of the AD8 for any other reason or purpose, including without limitation (a) the sale, distribution, publication, or transfer of the AD8 for any consideration or commercial value; (b) the creation of any derivative works of the AD8, including translations thereof; (c) the use of the AD8 as a marketing tool for the promotion or sale of any drug; (d) incorporation of the AD8 in an electronic medical record application software; and/or (e) any use of the AD8 in connection with research or clinical trials that are supported, in whole or in part, by any for-profit entity.

Individuals or corporations intending to use the AD8 for any use other than the Purpose stated above, including clinical trial or commercial purposes, must obtain WU's prior written permission, granted by an authorized representative of WU. Please contact Andrea Denny (314-362-0433) for more information.